Tumor-derived p53 mutants activate transcription from promoters of various growth-related genes. We tested whether this transactivation function of the mutant protein is sucient to induce tumorigenesis (`gain of function'). Tumor-derived mutant p53-281G transactivates the promoters of human epidermal growth factor receptor (EGFR) and human multiple drug resistance gene . To determine whether the C-terminal domain functions only as an oligomerization domain in mutant p53-mediated transactivation, we have replaced the tetramerization domain of p53 by a heterologous tetramerization domain; although this mutant protein formed tetramers in solution, it failed to transactivate signi®cantly. Therefore, for successful mutant p53-mediated transactivation, sequences near the C-terminus of mutant p53 are required to perform functions in addition to tetramerization. We also demonstrate that co-expression of a deletion mutant of p53 (p53 del 1-293), which retains the p53 oligomerization domain, inhibits this transactivation. p53 del 1-293 co-immunoprecipitates with p53-281G suggesting that hetero-oligomers of p53-281G and p53 del 1-293 are defective in transactivation. We also show that a cell line stably transfected with p53-281G expresses higher levels of endogenous NF-kB and proliferating cell nuclear antigen (PCNA) compared to that transfected with vector alone. On co-expression, p53 del 1-293 lowered the levels of NF-kB and PCNA in p53-281G-expressing cells. However, on co-expression, p53 del 1-293 did not inhibit the tumorigenicity and colony forming ability of p53-281G expressing cells. Our earlier work showed that a deletion of the C-terminal sequences of p53-281G overlapping the oligomerization domain obliterates`gain of function'. Taken together, the above information suggests that the C-terminal sequences have some critical role in`gain of function' in addition to transactivation.
Introduction
Wild-type p53 is a tumor-suppressor and is found to be mutated in a large number of human cancers (Donehower and Bradley, 1993; Greenblatt et al., 1994; Ko and Prives, 1996; Lane, 1994; Levine, 1993 Levine, , 1997 Lowe, 1999; Oren, 1999; Ozbun and Butel, 1995; Prives and Hall, 1999; Sheikh and Fornace, 2000; Soussi et al., 2000; Vogelstein et al., 2000) . Under normal situations wild-type p53 has a short half-life. However, under stress such as that caused by DNA damage p53 is stabilized and its intracellular level rises due predominantly to post-transcriptional modi®cations; p53 then induces G1-S arrest or apoptosis such that the damaged cell cannot perpetuate.
The majority of p53 mutations found in human cancer are missense in nature (Greenblatt et al., 1994; Levine et al., 1991; Soussi et al., 2000) . Presumably, tumor-derived p53 mutants cannot induce the degradation pathway activated by wild-type p53 through induction of MDM2. The resulting mutant protein is, thus, usually present at a relatively high level inside the cell (Haupt et al., 1997; Kubbutat et al., 1997; Prives and Hall, 1999) . Wild-type p53 acts as a sequence-speci®c transcriptional activator for a series of genes, including some that are involved in cell cycle control and apoptosis (Levine, 1997; Oren, 1999; Prives and Hall, 1999; Vogelstein et al., 2000) . Tumor-derived p53 mutants are defective in this sequence-speci®c transactivation. The wild-type protein can also repress promoters of a number of cellular and viral genes Ginsberg et al., 1991; Lechner et al., 1992; Santhanam et al., 1991; Seto et al., 1992; Subler et al., 1992 Subler et al., , 1994 . It has been shown to inhibit the endogenous expression of a number of genes (Lee et al., 1999; Murphy et al., 1996 Murphy et al., , 1999 Zhao et al., 2000) . Although the molecular mechanism behind the transcriptional repression is not completely clear, that tumor-derived p53 mutants have in general lost this function is suggestive of its functional importance.
Wild-type p53 has a well-de®ned domain structure (Ko and Prives, 1996) . Near the N-terminus it has two transactivation domains (amino acid 1 ± 42, 43 ± 63) (Candau et al., 1997; Subler et al., 1994; Zhu et al., 1998) , followed by a proline rich segment (amino acids 64 ± 91) (Sakamuro et al., 1997; Venot et al., 1998; Walker and Levine, 1996) . At the center is the DNA-binding domain (amino acids 100 ± 300) (Prives, 1994) ; this is followed by the presumptive nuclear localization signal (amino acids 316 ± 325) (Ko and Prives, 1996; Levine et al., 1991) and tetramerization domain (amino acids 320 ± 360); (Sturzbecher et al., 1992; Subler et al., 1994; Wang et al., 1993) and ®nally near the Cterminus is the basic domain (amino acids 360 ± 393) (Ko and Prives, 1996; Levine et al., 1991) . The Cterminal segment can take part in DNA strand transfer and reassociation (Bakalkin et al., 1994; Brain and Jenkins, 1994) . It can also bind to DNA dierent structural complexities, including DNA damaged by ionizing radiation or chemicals (Lee et al., 1995 (Lee et al., , 1997 Reed et al., 1995) . The C-terminal region can bind to DNA non-sequence-speci®cally; it is also the site for modi®cations such as phosphorylation, acetylation or binding to proteins such as 14-3-3 protein. These modi®cations seem to regulate p53's transcriptional and DNA-binding activities (Abarzua et al., 1995; Baudier et al., 1992; Fourie et al., 1997; Halazonetis et al., 1993; Hansen et al., 1996 , Hupp et al., 1992 , Takenaka et al., 1995 Waterman et al., 1998) .
A number of tumor-derived p53 mutants that are defective in transactivating genes normally induced by wild-type p53 can transactivate the promoters of growth-related genes such as, human proliferating cell nuclear antigen, EGFR, MDR-1, vascular endothelial growth factor, human interleukin 6, basic ®broblast growth factor, human heat shock protein 70, c-fos, insulin-like growth factor II, BAG-1, 15-lipoxygenenase and c-myc (Chin et al., 1992; Frazier et al., 1998; Kelavkar and Badr, 1999; Kieser et al., 1994; Margulies and Sehgal, 1993; Preuss et al., 2000 , Tsutsumi-Ishii et al., 1995 Ueba et al., 1994; Yang et al., 1999) . Lin et al. (1995) showed that amino acids at positions 22 and 23 in the N-terminal transactivation domain of the mutant protein p53 (Arg to Gly) [p53-281G] are required for transactivation of the MDR-1 promoter. They also showed that although murine 10(3) cells (free of endogenous p53) expressing p53-281G are tumorigenic in nude mice, cells expressing p53-281G with substitutions at amino acids 22 and 23 are not. This suggests a direct relationship between the transactivation ability of mutant p53 and the`gain of function' where mutant p53 procures a dominant oncogenic role.
More recently, using similar assay procedures as described above, we showed that the`gain of function' phenotype of tumor-derived p53 mutants also requires the C-terminally located oligomerization/nucleic acidbinding domain (Lanyi et al., 1998) . Whether the Cterminal region is only required to perform oligomerization or it has other function(s) necessary for mutant p53-mediated transactivation and/or`gain of function' is not known. Results of experiments with wild-type p53 in which the tetramerization domain has been replaced by a heterologous dimerization or tetramerization domain have shown that the heterologous oligomerization domain preserves wild-type p53-mediated transactivation and growth suppression (including G1-S inhibition) functions (Attardi et al., 1996a,b; Ishizaka et al., 1995; Pietenpol et al., 1994; Waterman et al., 1996) . However, no information is available regarding the consequence of replacement of the oligomerization domain of tumor-derived p53 mutants by heterologous oligomerization domains.
Here, we determine whether transactivation by tumor-derived mutant p53 is responsible for its`gain of function' phenotype and describe our investigation of the importance of oligomerization in the tumorderived p53-mediated transcriptional activation and gain of function'. We have also replaced the tetramerization domain of p53-281G by a coiled-coil dimerization motif or a modi®ed coiled-coil structure that codes for a tetramerization domain. Although the modi®ed heterologous coiled-coil tetramerization domain induced tetramerization of the mutant p53, it could not successfully substitute the domain in mutant p53-mediated transactivation of the EGFR promoter. This suggests that sequences near the C-terminus of mutant p53 are required to perform functions in addition to tetramerization for successful mutant p53-mediated transactivation. Since wild-type p53 with its tetramerization domain replaced by a heterologous dimerization/tetramerization motif retains transcriptional functions (Attardi et al., 1996a,b; Ishizaka et al., 1995; Pietenpol et al., 1994; Waterman et al., 1996) our work suggests a mechanistic dierence between transactivation mediated by wild-type p53 and its tumor-derived mutants. Heterooligomerization of wild-type p53 by a mini-protein with the oligomerization domain can eciently inhibit wild-type p53's biological functions leading to transformation of rat embryo ®broblasts Shaulian et al., 1992) . We, therefore, tested whether hetero-oligomerization between p53 del 1-293 and p53-281G would lead to inhibition of tumorigenicity (`gain of function') by p53-281G, and found that coexpression did not signi®cantly impact tumorigenesis. We ®nd that hetero-oligomerization between full-length mutant p53-281G and a p53 deletion mutant preserving the oligomerization domain inhibits transactivation of the EGFR and MDR-1 promoters by tumorderived mutant p53. We also show that a cell line stably transfected with p53-281G expresses higher levels of endogenous NF-kB2 and PCNA compared to that transfected with vector alone. On co-expression, p53 del 1-293 lowered the levels of NF-kB2 and PCNA in p53-281-expressing cells. Since sequences from 393-327 are required for tumorigenicity (Lanyi et al., 1998) , the C-terminal sequences must have a crucial role iǹ gain of function' in addition to transactivation.
Results
Replacement of the tetramerization domain of mutant p53 by a heterologous dimerization or tetramerization domain has a strong inhibitor effect on mutant p53-mediated transactivation Earlier, we have shown that several tumor-derived p53 mutants could transactivate promoters of a number of Oncogene Mutant p53-mediated transactivation D Deb et al growth-related genes including EGFR Ludes-Meyers et al., 1996) . However, the deletion mutant p53-281G del 393-327 that eliminates the oligomerization domain failed to transactivate (Lanyi et al., 1998; Ludes-Meyers et al., 1996) suggesting that proper oligomerization of a tumorderived p53 mutant is required for the transactivation function of the mutant protein. We, therefore, checked whether the C-terminally located oligomerization/nonsequence-speci®c nucleic acid binding domain is required only for oligomerization. It was earlier shown that replacement of the tetramerization domain of wild-type p53 by the dimerization domain consisting of the coiled-coil structure from the yeast GCN4 protein (or a derivative of the coiled-coil structure that results in a tetramerization domain) could eectively sustain wild-type p53's transactivation and growth suppression functions (Attardi et al., 1996a; Pietenpol et al., 1994; Waterman et al., 1996) . Performing similar experiments we wanted to determine whether a p53-281G derivative with such a replacement of the tetramerization domain would retain the transactivation function. Therefore, we studied the eect of expression of p53-281G, p53-281G 343cc (the coiled-coil structure from GCN4 is laced after the amino acid 343) (Pietenpol et al., 1994) and p53-281G TZ334NR (a modi®ed GCN4 coiled-coil structure is placed after amino acid 334 such that it becomes a tetramerization domain) (Waterman et al., 1996) on the activity of the EGFR promoter. Transfections were carried out in Saos-2 cells.
Luciferase assay results shown in Figure 1 demonstrate that p53-281G-mediated transactivation is not preserved by replacing its tetramerization domain by a heterologous dimerization/tetramerization motif suggesting that this region performs some vital function(s) required for mutant p53-mediated transactivation that cannot be substituted by a heterologous dimerization/ tetramerization domain. Amino acid residues 320 ± 360 of p53 code for the tetramerization domain (Sturzbecher et al., 1992; Subler et al., 1994; Wang et al., 1993) ; besides substitution of this domain (starting from amino acid 334), C-terminal amino acids past the oligomerization domain up to 393 are missing in p53-281G TZ334NR, and this segment may also play an important role in mutant p53-mediated transactivation. Therefore, we have tested one more mutant p53-281G TZ334NRI352, which has the sequences 352 ± 393 inserted after an Isoleucine at amino acid 352 following the TZ moiety. This mutant transactivated the best among all the domain replacement mutants. The Western blot analysis shown with the luciferase assay ®gure demonstrated equivalent amounts of expression by p53-281G and p53-281G TZ334NR, suggesting that expression de®ciency cannot explain the inability of p53-281G TZ334NR to transactivate. Thus, the results of our experiments suggest that the C-terminally located amino acids 352 ± 393 perform a vital function for mutant p53-mediated transactivation. Earlier, a similar conclusion was reached by Frazier et al. (1998) demonstrating a requirement for amino acids 370 ± 380 for transactivation the c-myc promoter by p53-281G.
Replacement of the tetramerization domain of mutant p53 by a heterologous tetramerization domain preserves tetramerization of the protein One possible reason for the failure of p53-281G TZ334NR and p53-281G TZ334NRI352 to transactivate the EGFR promoter eciently can be a defect in oligomerization in the context of mutant p53. We, therefore, tested whether p53-281G TZ334NR and p53-281G TZ334NRI352 exist predominantly as tetramers in solution. For this purpose we have used glutaraldehyde cross-linking assays as described earlier (Subler et al., 1994) .
We have synthesized 35 S-labeled p53-281G, p53-281G TZ334NR, p53-281G TZ334NRI352 and p53-281G del 393-327 using an in vivo transcription-translation system as described in Materials and methods. Synthetic proteins were incubated with glutaraldehyde at varying ®nal concentrations (Figure 2) . After cross-linking, proteins were analysed by gradient (4 ± 20%) sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis. The data shown in Figure 2 indicate that p53-281G, p53-281G TZ334NRI352 and p53-281G TZ334NR oligomerized, while p53-281G del 393-327 could not, although there may be some variations in tetramerization among p53-281G, p53-281G TZ334NRI352 and p53-281G TZ334NR. Since p53-281G TZ334NRI352 and p53-281G TZ334NR are capable of oligomerization into tetramers, the results of our experiments shown in Figure 1 demonstrate that for p53-281G-mediated transactivation, the C-terminally located oligomerization/nucleic acid binding domain is required for functions in addition to oligomerization.
Transactivation of the EGFR and MDR-1 promoters by the tumor-derived mutant p53-281G was inhibited by co-expression of p53 del 1-293
Hetero-oligomerization of wild-type p53 with miniproteins containing its C-terminal oligomerization domain results in inactivation of wild-type p53's function (Shaulian et al., 1992) . Therefore, to investigate the role of oligomerization further we tested whether such hetero-oligomerization of a tumor-derived mutant p53-281G would inactivate its transactivation potential.
Saos-2 cells were co-transfected with EGFR.Luc (Ludes-Meyers et al., 1996; Deb et al., 2001) or MDR-1.CAT (Chin et al., 1992; Lin et al., 1995) , the expression plasmid for p53-281G (or expression vector alone) and the expression plasmid for p53 del 1-293 (or expression vector alone). Transfections and CAT (or luciferase) assays were carried out as described in Materials and methods. Figure 3a ,b shows the CAT (and luciferase) assay data, it is apparent that although the tumor-derived p53-mutant transactivated the EGFR and MDR-1 promoters, the transactivation ability was reduced signi®cantly by the co-expression of p53 del 1-293. Western blot analyses examining expression of p53-281G and p53 del 1-293 for a representative experiment shown in the ®gure demonstrate that proteins were adequately expressed; thus, Figure 2 Replacement of the tetramerization domain of mutant p53 by a heterologous tetramerization domain preserves tetramerization of the protein. In vivo translated p53-281G and its derivatives (p53-281G TZ334NR, p53-281G TZ334NRI352 and p53-281G del 393-327) were incubated with the indicated concentrations of glutaraldehyde as described (Subler et al., 1994) . Samples were loaded onto a gradient (4 ± 20%) SDS polyacrylamide gel after cross-linking, electrophoresed, dried and autoradiographed. Positions of presumptive monomers, dimers, trimers and tetramers of p53 derivatives are indicated p53 del 1-293 forms complexes with p53-281G in vivo Next, we checked whether p53-281G would form heterooligomeric complexes with p53 del 1-293 in vivo. We cotransfected expression plasmids for p53-281G (or expression vector alone) and p53 del 1-293 (or expression vector alone) into Saos-2 cells. Twenty-four hours after transfection, cells were labeled in vivo with 35 Smethionine as described in Materials and methods. Cell extracts were used for immunoprecipitation analysis ( Figure 4 ). Although DO1 could not immunoprecipitate p53 del 1-293 alone (lane 4), it could precipitate both p53-281G and p53 del 1-293 when both were present (lane 3). This shows that p53 del 1-293 binds with p53-281G in vivo forming a hetero-oligomeric complex. Thus, results of these experiments (Figures 3 and 4) suggest that proper oligomeric forms of p53-281G are necessary for its transactivation function.
Effect of co-expression of p53 del 1-293 on the endogenous transactivation ability of p53-281G
Hetero-oligomerization of wild-type p53 with tumorderived p53 mutants (or polypeptides covering the oligomerization domain of p53) inhibit wild-type p53's biological functions leading to immortalization and transformation of rat embryo ®broblasts (Shaulian et al., 1992) . Since co-expression of p53 del 1-293 and p53 (wild-type or mutant) inhibits p53's transactivation (Deb et al., 1999; this communication) , it was important to test whether hetero-oligomerization between p53 del 1-293 and p53-281G would lead to inhibition of transactivation of endogenous genes by p53-281G.
To identify genes that are endogenously transactivated by p53-281G, we have used murine 10(3) cells that are devoid of endogenous p53 and have compared gene expression pro®les of cells stably transfected with p53-281G with that of cells stably transfected with vector (pCMVBamNeo, Hinds et al., 1990) alone. Microarray analysis done by Incyte Genomics (to be reported separately) indicated a number of genes that are expressed at a higher level in cells expressing p53-281G than in cells stably transfected with vector alone. We chose two such genes, PCNA and NF-kB2, to see the eect of coexpression of p53 del 1-293. We have used quantitative real-time PCR analysis of cDNA, made from total RNA, to determine the level of expression of PCNA and NF-kB2 RNAs. Figure 5 shows that the levels of both the genes are considerably higher in 10(3) cells expressing p53-281G compared to that in cells stably transfected with vector alone. Co-expression of p53 del 1-293 lowered the level of the RNAs to some extent, suggesting that hetero-oligomerization indeed inhibits transactivation by mutant p53. In- Effect of co-expression of p53 del 1-293 on the`gain of function' property of p53-281G as determined by tumorigenicity of 10(3) cells expressing the mutant protein Since co-expression of p53 del 1-293 and p53 (wild-type or mutant) inhibits p53's transactivation (Deb et al., 1999; this communication) , it was important to test whether hetero-oligomerization between p53 del 1-293 and p53-281G would lead to inhibition of tumorigenicity of mutant p53 expressing cells.
10(3) cells are murine cells that are devoid of endogenous p53 and are non-tumorigenic if injected subcutaneously in nude mice (Dittmer et al., 1993) . We have shown that although 10(3) cells expressing p53-281G form tumors, those stably expressing p53-281G del 393-327 (defective in oligomerization) could not (Lanyi et al., 1998) . This suggested a role for oligomerization in the`gain of function'. We, therefore, tested whether co-expression of p53 del 1-293, which inhibits p53-281G's transactivation ability, would also disrupt its tumorigenicity. Stable cell lines were generated from 10(3) cells (1) expressing p53-281G, (2) expressing p53 del 1-293, (3) expressing p53-281G and p53 del 1-293 and (4) stably transfected with vector alone [10(3) V4] (see Figure 6 ). Two dierent clones from each variety were injected subcutaneously into two or three dierent nude mice (two sites on each mouse) as described in Materials and methods. The mice were then observed for several weeks for appearance of tumors. As shown in Table 1 , 10(3) cells stably transfected with pCMVBam vector alone or stably expressing p53 del 1-293 did not show any tumor formation even after 5 months. For 10(3) cells expressing p53-281G and p53 del 1-293 tumors appeared within 1 ± 2 weeks of injection; similar is the situation with 10(3) cells expressing p53-281G alone. Since co-expression of p53 del 1-293 and p53-281G did not reduce tumorigenicity, hetero-oligomer formation may not interfere with mutant p53-mediated tumorigenesis. Figure 5 Eect of co-expression of p53 del 1-293 on the endogenous transactivation ability of p53-281G. Total RNA was prepared from 10(3) cells stably transfected with vector alone, p53-281G, p53 del 1-293, or p53-281G and p53 del 1-293 as described in the text. Quantitative real-time PCR was done as described in Materials and methods to determine the relative amounts of mRNA for NF-kB2 and PCNA genes. Histograms show the relative levels of (a) PCNA mRNAs and (b) NF-kB2 mRNAs (normalized to GAPDH levels in cells) in dierent stable transfectants of 10(3) cells Since co-expression of p53-281G and p53 del 1-293 in 10(3) cells did not interfere with tumorigenicity, we needed to verify in vivo hetero-oligomer formation between p53-281G and p53 del 1-293. Therefore, we prepared extracts from 10(3) cells expressing p53 del 1-293 alone and 10(3) cells expressing p53-281G and p53 del 1-293, and performed immunoprecipitation reactions (see Materials and methods) with DO1, an antibody that binds to the N-terminal region of p53. The immunoprecipitates were separated on an SDS polyacrylamide gel, and proteins transferred to a nitrocellulose membrane. The blot was then developed with PAb421 an antibody that recognizes a motif near the C-terminus and binds to both p53-281G and p53 del 1-293. The data shown in Figure 6 demonstrate that DO1 immunoprecipitates both p53-281G and p53 del 1-293 indicating heterooligomer formation between p53-281G and p53 del 1-293; as expected, DO1 did not interact with p53 del 1-293. Taken together, the results presented in Figures 5  and 6 suggest that hetero-oligomerization of p53-281G does not inhibit the tumorigenicity.
p53 del 1-293 did not inhibit colony formation by p53-281G
Expression of p53-281G gives growth advantage to cells expressing the mutant protein (Dittmer et al., 1993) ; we wanted to check whether p53 del 1-293 expression could in¯uence the cell growth advantage. We have used the colony formation assay as described Figure 6 Hetero-oligomers are produced between p53-281G and p53 del 1-293 in 10(3) cells stably expressing the two proteins. 10(3) cell lines stably transfected with vector alone, p53-281G, p53 del 1-293, or p53-281G and p53 del 1-293 were constructed and maintained as described in Materials and methods. Protein extracts from the respective cells were obtained by using the luciferase assay extraction procedure (see Materials and methods). Equal amounts of protein were loaded in each well of 10% SDS polyacrylamide gel, electrophoresed and the proteins transferred to a nitrocellulose membrane. The blot was developed using the monoclonal antibody PAb421. Positions of molecular weight markers are shown. The ®rst four lanes show the Western blot analysis. Cell extracts from 10(3) cells expressing p53 del 1-293 alone and 10(3) cells expressing p53-281G and p53 del 1-293 were prepared and immunoprecipitation reactions were performed (see Materials and methods) with DO1 an antibody that binds to the N-terminal region of p53. The immunoprecipitates were then separated on an SDS polyacrylamide gel followed by Western blot analysis. The blot was developed with PAab421, an antibody that recognizes a motif near the C-terminus and binds to both p53-281G and p53 del 1-293. Antibody DO1 was run and analysed by Western blot to depict the positions of light and heavy chains of IgG. The last ®ve lanes show this Western analysis Earlier, we showed that a deletion of the C-terminal sequences of p53-281G overlapping the oligomerization domain disrupts`gain of function', and here we demonstrate that hetero-oligomerization disables transactivation by p53-281G without eliminating`gain of function' (tumorigenicity). Taken together, this information suggests that the C-terminal sequences have a separate and critical role in`gain of function' in addition to that in transactivation.
Discussion
Since the C-terminal region of wild-type p53 harbors the oligomerization domain, and the oligomerization domain is necessary for the biological functions of wild-type p53 (Attardi et al., 1996a; Deb et al., 1999; Ishioka et al., 1997; Ozbun and Butel, 1995, Pietenpol et al., 1994; Sang et al., 1994; Subler et al., 1994; Waterman et al., 1996) , it was hypothesized that the C-terminal sequences for mutant p53 would be required for oligomerization, and the oligomerization may be critical for`gain of function' (Lanyi et al., 1998). We have tested this hypothesis using dierent approaches. An N-terminal deletion mutant of wild-type p53 that deletes amino acids 1 through 293 has been used as a tool to perform heterooligomerization studies. This mutant retains the entire oligomerization domain but dispenses o the transactivation domain and a large portion of the sequencespeci®c DNA-binding domain inactivating the transactivation and DNA-binding activities of wild-type p53 (Subler et al., 1994) . By co-transfection experiments followed by immunoprecipitation analysis we show that p53 del 1-293 forms hetero-oligomeric complexes with p53-281G (Figure 4 ). p53 del 1-293 inhibits p53-281G-mediated transactivation of the EGFR and MDR-1 promoters (Figure 3 ) suggesting that heterooligomerization inactivates transcriptional functions of mutant p53. We have also determined that coexpression of p53 del 1-293 and p53-281G reduced transactivation potential of p53-281G in stably transfected 10(3) murine cells. Although 10(3) cells stably transfected with p53-281G express 5 ± 6-fold more PCNA and NF-kB2 mRNA compared to the cells transfected with vector alone, co-expression of p53 del 1-293 reduced this transactivation considerably ( Figure  5 ). Our data, therefore, support the idea that proper oligomeric forms of mutant p53 are required for its transactivation function. We have used another approach to investigate the importance of oligomerization in mutant p53-mediated transactivation, and swapped the tetramerization domain of p53-281G with a coiled-coil dimerization domain from the yeast GCN4 protein (Pietenpol et al., 1994) or a modi®ed coiled-coil domain that acts as a tetramerization motif (Waterman et al., 1996) . Transcriptional data generated with these heterologous 3/6 0/6 p53-281G, clone 13 3/6 6/6 p53-281G, clone 4 2/4 4/4 p53-281G, clone 4, p53 del 3/6 6/6 1-293 clone 22 p53-281G, clone 4, p53 del 3/6 6/6 1-293, clone 10
Oncogene Mutant p53-mediated transactivation D Deb et al constructs showed that mutant p53-281G requires the C-terminally located oligomerization/non-sequence-speci®c nucleic acid-binding domain for its transactivation properties (Figure 1 ). This requirement is sequencespeci®c and not met by merely allowing the protein to oligomerize, as we demonstrated also that p53-281G with its tetramerization domain replaced by a heterologous tetramerization domain preserves the tetrameric structure of the protein (see Figure 2) , but disrupts the transactivation function (Figure 1) . However, replacement of the tetramerization domain of wild-type p53 by the dimerization domain, consisting of the coiled-coil structure from the yeast GCN4 protein (p53 343cc), could eectively sustain wild-type p53's transactivation and growth suppression functions (data not shown) (Attardi et al., 1996a; Ishioka et al., 1997; Pietenpol et al., 1994; Waterman et al., 1996) . Interestingly, in the context of wild-type p53 the replacement of its tetramerization domain by a derivative of the coiled-coil structure that results in a tetramerization domain could not activate transcription from the human p21 promoter as well as p53 343cc (data not shown). The reason for this apparent discrepancy is not known at the present time, but could be related to the DNA concentrations used in the dierent transfections (Subler et al., 1994) . Also, the wild-type p53 derivatives with heterologous dimerization/tetramerization domain inhibited the CMV immediate-early promoter signi®cantly; the extent of inhibition is comparable to that mediated by wild-type p53 (data not shown). Thus, the functions of wild-type p53 are preserved when a heterologous oligomerization domain replaces the oligomerization domain of p53 as shown earlier (Attardi et al., 1996a; Ishioka et al., 1997; Pietenpol et al., 1994; Waterman et al., 1996) . Taken together, these data strongly suggest that the C-terminal region of wild-type p53 mainly functions in oligomerization in transient-transfection transcription assays, whereas mutant p53 requires an additional function. Thus, there is a clear distinction in the requirement of the C-terminal domain for wild-type and mutant p53-mediated transcriptional functions.
For mutant p53-mediated transactivation, sequence requirements at the C-terminus are stringent, suggesting that the region is needed perhaps for sequence-speci®c functions in addition to oligomerization. A number of possible explanations for this requirement can be oered: (1) p53 has a nucleic acid binding activity associated with its C-terminal region (Ko and Prives, 1996; Reed et al., 1995) . It is possible that under appropriate conditions mutant p53 utilizes this activity to interact with the promoter to activate transcription. (2) A number of posttranslational modi®cations, e.g. phosphorylation and acetylation (Prives, 1998; Prives and Hall, 1999; Vogelstein et al., 2000) of wild-type p53 have been reported to occur in speci®c sites located near the Cterminus. Perhaps mutant p53 requires these modi®ca-tions for its transactivation function. (3) The C-terminal region could be a site for protein ± protein interaction [e.g., interaction needed with c-abl (Yuan et al., 1996) ] needed for mutant p53-mediated transactivation; speci®c interactions may occur between a transcription factor and the tetrameric C-terminal region of mutant p53. It is possible that overexpression of p53 del 1-293 would also compete for such modi®cations or functions with the intact protein causing an inhibition of transactivation. Analyses involving more speci®c mutations near the Cterminus along with functional assays are required before we can get a comprehensive idea about the function of the C-terminus in mutant p53-mediated transactivation.
We also investigated whether a homo-tetrameric structure of the mutant p53 protein is necessary for its gain of function' by studying the in¯uence of heterooligomerization on the`gain of function' as determined by tumorigenicity and colony forming ability of cells in which the mutant is expressed. We found that coexpression of p53 del 1-293 and p53-281G caused inhibition of transactivation of p53-281G, and earlier, we and others have shown that transactivation is directly related to`gain of function ' (Lanyi et al., 1998; Lin et al., 1995) . Therefore, a likely scenario would be that coexpression of p53 del 1-293 would hinder p53-281G's gain of function' property as determined by the tumorigenicity assay. Our results shown in Table 1 , however, indicate that co-expression of p53 del 1-293 does not inhibit tumorigenicity of 10(3) cells expressing p53-281G. Results from our co-immunoprecipitation experiments (Figure 6 ) demonstrate that p53-281G forms hetero-oligomers with p53 del 1-293 in 10(3) cells stably expressing both proteins. This observation argues that hetero-oligomerization although disrupts transactivation capacity of mutant p53 cannot eliminate its`gain of function' (tumorigenicity) property noticeably. The colony formation assay also indicates that p53 del 1-293 had no signi®cant impact on growth of p53-281G expressing cells; it behaved very similarly to the vector control. In these assays, however, wild-type p53 and p73 a reduced colony numbers signi®cantly for cells expressing p53-281G, showing that the growth advantage induced by p53-281G was countered better by the growth suppressors. Thus, hetero-oligomerization between p53-281G and p53 del 1-293 may not inhibit p53-281G's growth enhancing properties, although it does inhibit its transactivation property. This observation goes against the notion that the transactivation property of the tumor-derived p53 mutants may be responsible for thè gain of function'. We must add though that before we draw such a conclusion it must be proven that all the mutant p53 protein molecules are complexed with p53 del 1-293, because it is possible that any free mutant p53 molecule could induce the growth enhancement. Although we have shown that p53 del 1-293 and p53-281G forms hetero-oligomeric complexes in 10(3) cells expressing the two proteins, it is possible that some p53-281G molecules are still free. Because of extended number of passages that the cells had to pass through, it is also possible that the 10(3) cells expressing p53-281G became spontaneously transformed independent of the involvement of p53-281G; in that case neutralization of mutant p53 would not reduce its oncogenicity. 10(3) cells indeed have a tendency to become spontaneously tumorigenic (data not shown).
Interestingly, expression of`gain of function' mutants of p53 has also been shown to enhance drug resistance, interfere with p53-independent apoptosis, and induce centrosome abnormalities in cells expressing them (Blandino et al., 1999; Li et al., 1998; Murphy et al., 2000; Sigal and Rotter, 2000; Wang et al., 1998) . It is not known whether mutant p53-mediated transactivation is involved as the etiologic agent for these phenotypes. Gualberto et al. (1998) reported that some mutant p53 confer a dominant`gain of function' phenotype that disrupts the spindle checkpoint control. They also showed that for that function the mutant protein does not require transactivation. Thus, it is possible that somè gain of function' is achievable even in the absence of the transactivation function of mutant p53.
How mutant p53 induces`gain of function' is still an open question. It is possible that the newly found family members of p53, such as p73 and p63, may act as surrogate p53 in p53's absence and all p53 mutants do is to neutralize their activity, perhaps by hetero-oligomerization, and some such evidence have been presented (Di Como et al., 1999; Gaiddon et al., 2001; Marin et al., 2000; Strano et al., 2000) . It has also been shown that for its neutralizing and hetero-oligomerization activity aecting p73 or p63 the mutant p53 protein requires only its central`DNA-binding domain'. However, earlier work (Lanyi et al., 1998; Lin et al., 1995) indicate that the transactivation domain and C-terminally located region overlapping the oligomerization and non-sequencespeci®c nucleic acid-binding domains are required for gain of function'. This shows that sequences outside the region needed for neutralizing p73 are needed for`gain of function'. Therefore, the`gain of function' cannot be fully explained by p73-mutant p53 interactions. Also, our attempts to identify endogenous p73-p53-281G complexes in 10(3) cells expressing p53-281G failed so far (data not shown). This, however, suggests that even if p73-p53-281G complexes are formed, they are low in number. The work presented here shows that heterooligomerization inhibited but not obliterated transactivation, and Dittmer et al. (1993) reported that the tumorderived p53 mutants that dier in transactivation did not dier in their tumorigenicity suggesting that any remnant transactivation might be enough to induce`gain of function'. Thus, a small fraction of free mutant p53 may induce oncogenic transformation by transactivating expression of critical growth-related genes. At this point, it is not clear whether mutant p53-mediated transactivation is the cause of`gain of function'. Thus, it is necessary to identify target genes that are aected by`gain of function' directly, and to determine whether transactivation of these genes lead to increased oncogenesis (`gain of function').
Materials and methods

DNA
The p53 and p73 expression plasmids contained the human p53 and p73 cDNAs under the regulation of the CMV immediate-early promoter in the pCMVBam expression vector (Hinds et al., 1990; Subler et al., 1992) . The Nterminal deletion derivative p53 del 1-293 was generated in the context of the human wild-type p53 cDNA as described earlier (Subler et al., 1994) . p73 a and p73 b cDNAs have been cloned in such a way that they have a FLAG epitope at the N-terminus when converted into the respective proteins (Deb et al., 2001) . p53 mutants, p53 343cc and p53 TZ334NR, have been described earlier (Pietenpol et al., 1994; Waterman et al., 1996) . p53 343cc had sequences from amino acids 344 to 393 replaced with the coiled-coil structural domain from the yeast GCN4 protein, while p53 TZ334NR had sequences from amino acids 334 to 393 replaced by a modi®ed coiledcoil structure de®ning a tetramerization domain. p53-281G 343cc and p53-281G TZ334NR contained the amino acid substitution at the position 281 from Arg to Gly; these clones were constructed by standard sub-cloning techniques by replacing a restriction fragment of the wild-type p53 cDNA overlapping the sequence coding for amino acid 281 with the corresponding fragment from p53-281G cDNA. All the coding sequences were cloned in the pCMVBam vector in the correct orientation downstream of the CMV immediate-early promoter. pHyg (Invitrogen) contained the hygromycin resistance gene cloned under the herpes simplex virus thymidine kinase promoter (Clontech).
The chloramphenicol acetyltransferase (CAT) plasmids utilized the Escherichia coli CAT gene under the transcriptional control of the MDR-1 (Lanyi et al., 1998) promoter. The luciferase plasmids used the ®re¯y luciferase (luc) gene under the control of the human EGFR and p21 promoters (Deb et al., 2001; el-Deiry et al., 1993) .
Cell culture and transfection
Human osteosarcoma (Saos-2) cells were cultured and transfected by the calcium phosphate-DNA co-precipitation method, as described previously . In a typical experiment 3610 6 cells in a 10 cm dish were transfected with indicated amounts of plasmids. Some transfections were done using Lipofectamine 2000 (Life Technologies) using 24-well plates following manufacturer's protocol. For 24-well plates each well was transfected with 1 mg total DNA. In general, the promoter luciferase construct and the eector plasmid are added at 170 ng per well, and the rest of the 1 mg DNA came from pUC 19 DNA.
Chloramphenicol acetyltransferase assay
Cells were harvested 36 ± 40 h post-transfection and lysed by three successive cycles of freezing and thawing. Extracts were normalized for protein concentration and assayed for CAT enzyme activity as described earlier (Ludes-Meyers et al., 1996) . Multiple independent experiments (three or more) were done to determine the standard deviations. CAT activity was detected by thin-layer chromatographic separation of [ 14 C]-chloramphenicol from its acetylated derivatives followed by autoradiography. Quantitation was done using a Phosphorimager (Molecular Dynamics).
Luciferase assay
Luciferase assays were carried out using a commercial kit from Promega as suggested by the vendor, and luminescence was measured in a Luminometer made by Turner Designs. Cells were harvested 36 ± 40 h after transfection, and extracts were prepared as suggested. As described for the CAT assay, equal amounts of protein from each extract were used for the luciferase assay. Relative luciferase activity was plotted on the Y-axis and the value of the vector control was set to 100%.
In vivo labeling of cellular proteins and immunoprecipitation
Saos-2 cells were transfected with p53 expression plasmids (or expression vector alone) as described in the text. Twenty-four hour post-transfection labeling of cellular proteins was carried out with 35 S-methionine for 2 h, after which cells were harvested and cell extracts prepared as described earlier . Immunoprecipitations were carried out for 14 h at 48C using indicated monoclonal antibodies as described earlier . PAb421 (Lane and Crawford, 1979; Vojtesek et al., 1992) was used to bind p53 proteins with an intact C-terminus (intact p53-281G as well as p53 del 1-293) and DO1 (Lane and Crawford, 1979; Vojtesek et al., 1992) was used to detect p53 proteins with an intact N-terminus (p53-281G but not p53 del 1-293).
Establishment of stable 10(3) cell lines expressing p53 del 1-293 (or p53-281G and p53 del 1-293) Untransfected 10(3) cells (Dittmer et al., 1993) or 10(3) cells stably expressing p53-281G (Lanyi et al., 1998) were transfected with pCMVBam p53 del 1-293 and pCMVBam neo (Hinds et al., 1990) or pCMVBam p53 del 1-293 and pHyg (Clontech), respectively, using the calcium phosphate precipitation technique . Forty-eight hours after transfection, cells were washed, trypsinized, subcultured at 1 : 4, and plated into selective media supplemented with 200 mg/ml G-418 (active concentration) for previously untransfected 10(3) cells and 200 mg/ml G-418 and 200 mg/ml hygromycin for p53-281G-expressing cells. Cells were maintained in the selective media with twice weekly changes of media. After 14 ± 21 days in selective media, cells from individual antibiotic-resistant colonies were isolated and expanded into cell lines. Western blot analyses were used to detect p53 del 1-293 or p53 del 1-293 and p53-281G expressed in these cell lines.
Immunoprecipitation followed by Western blot analysis to determine in vivo complex formation between p53-281G and p53 del 1-293
In vivo complex formation between p53-281G and p53 del 1-293 in 10(3) cells stably transfected to express p53-281G and p53 del 1-293 was done by immunoprecipitation of p53-281G with an antibody (DO1) that recognizes a motif on the Nterminal part of the protein and is absent in p53 del 1-293. We carried out the procedure following the method described by Leng et al. (1995) . Brie¯y, cells from a 10 cm dish were harvested in 4 ml of 10 s buer (containing 250 mM HEPES, pH 7.2, 1.5% NP40, 0.5% Triton X-100, 0.025% SDS, 50 mM sodium phosphate buer, pH 7.0, 5 mM NaF, 0.5 mM phenyl methyl sulphonyl¯uoride and 2.5 mM dithiothreitol) as described. One ml of the extract was then incubated with 1 or 2 mg of p53 antibody DO1 and 16 ml of protein A agarose (Calbiochem) and shaken overnight (head-to-tail) at 48C. The following morning, the immunoprecipitate was washed three times with 10 s buer and once with a buer containing 10 mM Tris pH 7.5, 50 mM NaCl, 0.5% sodium deoxycholate and 0.5% Triton X-100. The pellet was then suspended in 20 ml of 26 Laemmlli loading buer, boiled and analysed by 15% SDS polyacrylamide gel electrophoresis, followed by Western blot analysis using PAb421 as the probe.
Tumorigenicity assay
The tumorigenic potential of 10(3) cells expressing p53 derivatives was tested using nude mice. Cells (5610 6 per site) were subcutaneously injected into¯anks of athymic nude mice (National Cancer Institute) and tumor development was monitored as described (Dittmer et al., 1993; Lanyi et al., 1998) .
Colony formation assay 10(3) cells stably transfected with the vector pCMVBam Neo (Hinds et al., 1990) or stably expressing p53-281G (Lanyi et al., 1998) in each 10 cm dish were transfected with 1 mg of pHyg and 5 mg (1) pCMVBam , (2) pCMVBam wild-type p53 , (3) pCMVBam FLAG p73 a (Deb et al., 2001) , (4) pCMVBam FLAG p73 b Deb (Deb et al., 2001) , or (5) pCMVBam p53 del 1-293 (Subler et al., 1994) . Transfections were done by calcium phosphate precipitation technique as described earlier (Lanyi et al., 1998) . After 48 h of transfection cells were subcultured 1 : 4; hygromycin was added next day at 200 mg/ ml to start the selection process. Neomycin (G418 at 200 mg/ ml) was also added to those cells selected earlier for neomycin resistance as described before (Lanyi et al., 1998) . Every 2 ± 3 days media was changed. After 3 weeks, cells were ®xed with methanol and stained with methylene blue.
Western blot analysis
Western blot analysis was carried out after SDS polyacrylamide gel electrophoresis using monoclonal antibodies against p53 or FLAG and a commercial kit (Promega) for labeling with an alkaline phosphatase-conjugated secondary antibody. Manufacturer's protocol was followed for this procedure.
Oligomerization assays with in vitro-synthesized intact p53-281G and its derivatives Analyses for the presence of oligomeric forms of p53-281G and its derivatives were carried out as described (Subler et al., 1994) . Brie¯y, human p53-281G and its derivatives were generated by a coupled in vivo transcription-translation system (Promega) and were incubated with glutaraldehyde at varying ®nal concentrations at 378C for 15 min. After cross-linking, proteins were boiled in 26 Laemmli loading dye (Subler et al., 1994) , subjected to gradient (4 ± 20%) SDS-polyacrylamide gel electrophoresis, and visualized by autoradiography.
RNA isolation and microarray hybridization analysis
Total RNA was isolated from 10(3) cells stably transfected with vector alone [pCMVBamNeo (Lanyi et al., 1998) ], pCMVBamNeo and expression plasmid for p53-281G, pCMVBamNeo and expression plasmid for p53 del 1-293, and pCMVBamNeo and expression plasmids for p53-2981G and p53 del 1-293 using Trizol (Gibco) reagent following manufacturer's protocol. Quality of the RNAs was checked by 1.2% agarose Tris-borate-EDTA gel electrophoresis.
Microarray analysis from RNA from 10(3) cells stably transfected with (1) vector alone [pCMVBamNeo (Lanyi et al., 1998) ] and (2) pCMVBamNeo and expression plasmid for p53-281G was done by Incyte Genomics, Inc. (Palo Alto, CA, USA) starting from the whole RNA that we sent. Brie¯y, polyadenylated RNA was isolated with the OligoTex (Qiagen) RNA kit. Polyadenylated RNA was reverse transcribed to generate Cy3-and Cy5-labeled cDNA probes, respectively. cDNA probes were competitively hybridized to a mouse Unigene 1 cDNA microarray (Incyte Genomics, Inc.) containing immobilized cDNA fragments (average cDNA length, 500 ± 5000 base pairs). Cy3 and Cy5 uorescence were imaged individually, and the normalized ratios of Cy3/Cy5¯uorescence at a given spot on the microarray were used to calculate dierential gene expression.
Quantitative real-time PCR
Relative quantitation of gene expression was performed using quantitative real-time PCR (QPCR). The relative amount of each sample was calculated from a standard curve after employing the Fit Points algorithm for quanti®cation. This expression value was normalized to a housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Krause et al., 2000) . A relative gene expression was determined by assigning 10(3) V4 [10(3) cells stably transfected with the vector pCMVBam Neo (Hinds et al., 1990) ] a relative value of 1.0, with all other values relative to 10(3)V4. This method is described in detail by Johnson et al. (2000) ; Tanguay et al. (2000) . Following is a brief description of the entire process.
(1) cDNA synthesis Total RNA was isolated from 5610 6 mouse 10(3) cells stably transfected to express p53 281G, clone 4, p53D1.291, clone 10, p53 281GD1-293, clone 22, and vector (V4) alone using Trizol reagent (Gibco BRL, Gaithersburg, MD, USA) following the manufacturer's instructions. Ten micrograms of total RNA was treated with RA1 Rnase-free DNase (Promega, Madison, WI, USA), followed by phenol extraction, chloroform extraction and ethanol precipitation. cDNA was synthesized with random hexamer using the Thermoscript RT ± PCR System (Gibco BRL) according to the manufacturer's protocol. cDNA volume was increased twofold to decrease pipetting error.
(2) Primers Primers were designed using Oligo 5.0 Software (National Biosciences, Inc, Plymouth, MN, USA) and were synthesized by Integrated DNA Technologies. Primer optimization was performed to determine the optimal concentration of MgCl 2 and annealing temperature for each primer set.
(3) Relative standard curves Relative standard curves were constructed for each target gene using previously generated PCR products of the target. Serial dilutions were made, and were given arbitrary values corresponding to the dilutions.
(4) Quantitative real-time PCR Quantitative real-time PCR was performed using a LightCycler (Roche). Each reaction (20 ml) contained 2 ml of the respective diluted cDNA, primers (0.5 mM), and 4 mM MgCl 2 , and FastStart Reaction Mix SYBR Green I, (Roche) which includes FastStart Taq DNA polymerase, reaction buer, dNTPs, and SYBR Green I dye. A negative control was included in each QPCR run.
Except for the composition of the standard curves, each reaction was performed in triplicate. All samples were treated with an initial denaturation step at 958C for 10 min to activate the enzyme and denature the cDNA. Samples investigated with GAPD primers (F) 5'-CCAGCCTCGTCCCGTAGACA-3' and (R) 5'-GCCTCACCCCATTTGATGTTAGTG-3' underwent 40 cycles of the following: 958C for 15 s, 568C for 5 s, and 708C for 12 s. Samples checked with PCNA primers (F) 5'-GATAAAGAAGAGGAGGCGGTAA-3' and (R) 5'-ACACGCTGGCATCTCAGGAGCA-3' underwent 45 cycles of 958C for 15 s, 518C for 5 s, 728C for 12 s. NFkB2 samples (F) 5'-TGGCCCCTATCTGGTGATTGT-3' and (R) 5'-ACACTCCCAACTCTGAACACTGCT-3' underwent 50 cycles of 958C for 15 s, 568C for 5 s, and 728C for 10 s. The presence of SYBR Green I, a non-speci®c dye which binds to double-stranded DNA, can be detected bȳ uorescence at the end of each extension step. In this way the synthesis of DNA is determined in real-time. Agarose gel electrophoresis and melting curve analysis were used to demonstrate the presence of a speci®c product.
